Some experimental studies of systemic inflammation during sepsis showed that the application of BMMSCs is preferable due to a higher expression of the soluble cytokine receptors like soluble tumor necrosis factor receptor (sTNFR1) and soluble vascular endothelial growth factor receptor-1 (sVEGFR1) [32], while other studies indicated the beneficial effects of ASCs due to their easier availability [33] or showed no differences between BMMSCs on systemic inflammation during sepsis [34]. The gene discussed is FLT1; the disease is Sepsis.